Clinical Trials Logo

Skin Neoplasms clinical trials

View clinical trials related to Skin Neoplasms.

Filter by:

NCT ID: NCT05267691 Recruiting - Clinical trials for Dermatological Tumors

Pathological Characteristics of Basal Cell Carcinoma

Start date: January 1, 2017
Phase:
Study type: Observational

A hospital based cross-sectional study was conducted from 2017 to February 2021. Clinical history, examination and histopathological variants were collected from medical files and pathology reports. Confirmation of pathology was done in all the patients visiting skin and plastic surgery department with suspected lesions.

NCT ID: NCT05257486 Enrolling by invitation - Clinical trials for Non-melanoma Skin Cancer

Post-market Multi-Center RETRO-Prospective Study to Assess Long-term Clinical Outcomes NMSC Patients Treated With eBx

Start date: March 9, 2022
Phase:
Study type: Observational

The purpose of this retrospective-prospective study is to evaluate lesions after treatment for BCC or SCC NMSC in order to gain a better understanding of the durability of the treatment, and risk of late toxicities for this patient population.

NCT ID: NCT05246163 Recruiting - Skin Cancer Clinical Trials

ARTIficial Intelligence-based Smartphone Application for Skin Cancer Detection

ARTIS
Start date: January 1, 2020
Phase:
Study type: Observational

The aim of this project is to assess whether a specific smartphone application (Skinvision App®) can be used as a tool to preselect skin lesions suspicious for skin cancer that require urgent medical advice.

NCT ID: NCT05240209 Not yet recruiting - Skin Cancer Clinical Trials

Skin Cancer, Self Skin Examination and Sun Protection Behaviors Training

RCT
Start date: May 30, 2023
Phase: N/A
Study type: Interventional

Introduction: Cancer is a serious disease with a high mortality rate in the world and in Turkey today. Skin cancer, which is among the most common types of cancer, is increasing every year in many countries in the world such as Australia, America, New Zealand, and in Turkey. The most dangerous type of skin cancer with a high mortality risk is melanoma. According to the Turkish Cancer Statistics, melanoma is among the ten most common cancer types among children aged 0-14 years. This situation constitutes a public health problem. Aim: This research was planned to determine the effect of education given to parents of secondary school students about skin cancer, Skin Self Examination (SSE) and Sun Protection Behaviors on their children's sun protection behaviors.

NCT ID: NCT05200143 Active, not recruiting - Clinical trials for Refractory Cutaneous Melanoma

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Start date: June 8, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory metastatic cutaneous melanoma.

NCT ID: NCT05188729 Recruiting - Skin Cancer Clinical Trials

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

Start date: February 1, 2022
Phase: Phase 2
Study type: Interventional

This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell carcinoma (BCC). The study is expected to enroll approximately 80 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch or shave biopsy).

NCT ID: NCT05179824 Recruiting - Breast Cancer Clinical Trials

Tempus Priority Study: A Pan-tumor Observational Study

Start date: October 19, 2020
Phase:
Study type: Observational

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

NCT ID: NCT05176470 Active, not recruiting - Stage IV Melanoma Clinical Trials

Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients

Start date: July 1, 2022
Phase: Phase 1
Study type: Interventional

This phase I/II trial tests the safety and side effects of LN-144 (Lifileucel) and pembrolizumab in treating patients with stage IIIB-D or stage IV melanoma that has spread to nearby tissue or lymph nodes. Biological therapies, such as LN-144 (Lifileucel), use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lifileucel and pembrolizumab may make the tumor smaller.

NCT ID: NCT05170035 Recruiting - Skin Cancer Clinical Trials

Autologous Patch Healing vs. Secondary Intention Healing After Mohs Micrographic Surgery

Start date: February 1, 2022
Phase: N/A
Study type: Interventional

The primary objects of this study is to explore the potential effect of the autologous patch to optimize wound healing after skin cancer surgery with Mohs micrographic surgery (MMS) in the face in a randomized controlled trial comparing autologous patch healing versus secondary intention healing.

NCT ID: NCT05146622 Completed - Skin Cancer Clinical Trials

Virtual Sun Safe Workplaces Ph I

SSW Works
Start date: October 28, 2021
Phase:
Study type: Observational

Americans who work outdoors are exposed to an extreme amount of solar ultraviolet radiation over a lifetime that substantially increases their risk for developing skin cancer. In Phase I, the feasibility of a virtual learning environment (VLE) for distributing our effective Sun Safe Workplaces (SSW) intervention to American employers will be established with input from senior managers and Hispanic and African American outdoor workers and development and evaluation of a prototype of the SSW Works VLE. In Phase II, the full SSW Works will be produced and tested for effectiveness at improving outdoor workers' sun protection in a randomized trial enrolling employers nationwide.